Triple negative breast cancer (TNBC), which accounts for 10-20% of all breast cancers, lacks any of the receptors that are commonly found in breast cancer. Because hormone therapy and other drugs rely on these receptors for effective treatment, TNBC is usually treated with chemotherapy only. Recent genomic sequencing studies have revealed a lack of TNBC-specific mutations. Identifying genetic targets for TNBC could give patients with this form of breast cancer a brighter future and a better shot at recovery.
Lee, S., Hu, Y., Loo, S. K., Tan, Y., Bhargava, R., Lewis, M. T., & Wang, X.-S. (2020). Landscape analysis of adjacent gene rearrangements reveals BCL2L14–ETV6 gene fusions in more aggressive triple-negative breast cancer. Proceedings of the National Academy of Sciences, 117(18), 9912–9921. https://doi.org/10.1073/pnas.1921333117